title: [Autoimmune hepatitis].
abstract: Autoimmune hepatitis is chronic liver disease with two subtypes, type 1 with anti nuclear or smooth muscle antibodies and type 2 with LKM1 or LC1 antibodies, and both with hypergammaglobulinemia and typical histology. Prevalence of AIH is between 10 to 17 per 100000 in Europe. Up to 20-40 % of cases present with acute hepatitis. Budesonide can be used as a first line induction therapy in non-cirrhotic patients, and tiopurines, mercaptopurine or mycophenolic acid as maintenance therapies. Patients not responding to conventional therapy can be treated with ciclosporin, tacrolimus or rituximab or finally with liver transplantation.
authors.affiliation: Helsingin yliopisto, kliininen laitos ja HYKS, medisiininen tulosyksikkö, gastroenterologian klinikka.
authors.forename: Martti
authors.initials: M
authors.lastname: Färkkilä
mesh_terms: D019819:Budesonide / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D005938:Glucocorticoids / Q000627:therapeutic use; D019693:Hepatitis, Autoimmune / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation; D015995:Prevalence
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D019819:Budesonide